#### Annex to Form PCT/ISA/206 **COMMUNICATION RELATING TO THE RESULTS** OF THE PARTIAL INTERNATIONAL SEARCH

Internetional Application No PCT/US2007/060581

- 1. The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:
- see 'Invitation to pay additional fees' 2. This communication is not the international search report which will be established according to Article 18 and Rule 43.
- 3.If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.
- 4.If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the International application for which such fees will have been paid.

Calegory °	Citation of document, with indication, where appropriate, of the relevant passages	1-3, 15-22	
X	WO 01/67991 A (YANG JUN [US]) 20 September 2001 (2001-09-20) page 4, line 4 - page 10, line 6		
X	EP 1 518 517 A (SUN BIOMEDICAL LTD [BM]) 30 March 2005 (2005-03-30) the whole document	1-3, 15-22	
<b>X</b> .	EP 1 600 125 A (BARD INC C R [US]) 30 November 2005 (2005-11-30) claims; figures	1-3, 15-22	
<b>X</b> .	WO 99/40874 A (STEINKE THOMAS A [US]) 19 August 1999 (1999-08-19) abstract	1-3, 15-22	
X	EP 1 600 122 A (MEDTRONIC VASCULAR INC [US]) 30 November 2005 (2005-11-30) claims; figures	1-3, 15 <b>-2</b> 2	
. 41			
0			

- \*A\* document defining the general state of the art which is not considered to be of particular relevence
- "E" eertler document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to esteblish the publication date of enother citation or other special reason (es specified)
- document referring to en oral disclosure, use, exhibition or other means
- document published prior to the Internetional filing data but later than the priority date claimed
- \*T\* later document published efter the International filing date or priority date and not in conflict with the epplication but clied to understand the principle or theory underlying the legistration.
- 'X' document of particular relevence; the claimed invention cannot be considered novel or cannot be considered to involve en inventive step when the document is taken alone
- document of particular relevance; the claimed invention cannot be considered to involve en inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled In the art.
- "&" document member of the same petent family

Special categories of cited documents:

# **Patent Family Annex**

Information on patent family members

International Application No
PCT/US2007/060581

Patent doct cited in searc		Publication date		Patent family member(s)		Publication date
WO 01679	91 A	20-09-2001	AU US US	4356701 6379382 2002062147	B1	24-09-2001 30-04-2002 23-05-2002
EP 15185	17 A	30-03-2005	NONE			
EP 16001	25 A	30-11-2005	NONE			<del></del>
WO 99408	74 A	19-08-1999	AT AU CA CN DE EP JP RU US US	314023 754566 2239499 2322050 1292668 69929175 1056414 3749437 2002502665 2217098 6033436 6224626	B2 A A1 A T2 A1 B2 T C2 A	15-01-2006 21-11-2002 30-08-1999 19-08-1999 25-04-2001 22-06-2006 06-12-2000 01-03-2006 29-01-2002 27-11-2003 07-03-2000 01-05-2001
EP 16001	22 A	30-11-2005	NONE			

## **PATENT COOPERATION TREATY**

# **PCT**

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/IS	see Form PCT/ISA/220				
BSCI02100WO	ACTION	as well as, where applicab					
International application No.	International filing date (day/mont/	(Earliest) Priority	Date (day/month/year)				
PCT/US2007/060581	16/01/2007	0	1/02/2006				
Applicant							
BOSTON SCIENTIFIC SCIMED,	INC.		0				
This International search report has been prepared by this international Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the international Bureau.							
This International search report consists o	a copy of each prior art document c						
		to a nr ano report.					
a translation of the of a translation ful	international search was carried out pplication in the language in which is international application into	was filed , which nal search (Rules 12.3(a) and	', ''				
2. Certain claims were fou	nd unsearchable (See Box No. II)						
3. X Unity of invention is lack	3. X Unity of invention is lacking (see Box No III)						
4. With regard to the title,							
X the text is approved as su	bmitted by the applicant						
the text has been establis	hed by this Authority to read as folio	ws:					
i							
			_				
			; 				
5. With regard to the abstract,							
the text is approved as su							
X the text has been establis may, within one month fro	hed, according to Rule 38.2(b), by the matter of mailing of this Internation.	is Authority as it appears in B ional search report, submit co	ox No. IV. The applicant mments to this Authority				
6. With regard to the <b>drawings</b> ,							
a. the figure of the drawings to be p	ublished with the abstract is Figure	No. 2a					
X as suggested by t	he applicant						
	s Authority, because the applicant fa						
1	s Authority, because this figure bette e published with the abstract	r characterizes the invention	RECEIVED				
Form PCT/ISA/210 /first shoots / April 2005)	<u> </u>		- AUG 1 7 2897				

International application No.

#### INTERNATIONAL SEARCH REPORT

PCT/US2007/060581

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

A medical device includes a carrier and an agent. The agent is formulated to control inflammation of biological tissue, such as heart tissue, and is releasably coupled to the carrier. The carrier (130) is configured to be disposed in operative proximity to the biological tissue to be treated by the agent (120). In one embodiment, the carrier is configured to release the agent or otherwise deliver the agent to the biological tissue, thus controlling inflammation of the tissue. Also, a method to improve healing of biological tissue includes placing a medical device proximate to the heart of a patient, where the medical device has a carrier and an agent configured to control inflammation, the agent is releasably coupled to the carrier. In one embodiment, the method includes causing the agent to be released from the

#### いしにいいみししいみた うにんりしつ ガビアしばし

International application No PCT/US2007/060581

		10170	52007/060581	
a. Classi INV .	IFICATION OF SUBJECT MATTER A61F2/06			
According to	o Internetional Patent Classification (IPC) or to both national classific	cetion and tPC		
B. FIELDS	SEARCHED			
	ocumentetion searched (classification system followed by classifical $A61L$	ion symbols)		
Documenta	tion searched other then minimum documentation to the extent that	such documents are included in the	fields searched	
	data base consulted during the international search (name of data buternal	ase and, where practical, search terr	ns used)	
C. DOCUM	IENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with Indication, where appropriate, of the re	elevant passages	Relevant to claim No.	
X	W0 01/67991 A (YANG JUN [US]) 20 September 2001 (2001-09-20) page 4, line 4 - page 10, line 6		1-3, 15-22	
X	EP 1 518 517 A (SUN BIOMEDICAL L 30 March 2005 (2005-03-30) the whole document	1-3, 15-22		
X	EP 1 600 125 A (BARD INC C R [US 30 November 2005 (2005–11–30) claims; figures	1-3, 15-22		
Χ .	WO 99/40874 A (STEINKE THOMAS A 19 August 1999 (1999-08-19) abstract	1-3, 15-22		
X	EP 1 600 122 A (MEDTRONIC VASCUL [US]) 30 November 2005 (2005-11-claims; figures	1-3, 15-22		
Fur	ther documents are listed in the continuation of Box C.	X See patent family annex.		
* Spedal docume constitute filling the state of the state	categories of cited documents : nent defining the general state of the art which is not dered to be of particular relevance document but published on or efter the international	<ul> <li>"T' later document published after or priority date and not in conficited to understand the princip invention</li> <li>"X" document of perticular relevant cannot be considered novel or involve an inventive step where</li> <li>"Y" document of particular relevant or particular relevant</li> </ul>	lict with the application but one or theory underlying the ce; the claimed Invention connot be considered to not the document is taken alone as; the claimed invention we an inventive step when the le or more other such docuge g obvious to a person skilled	
Date of the	e actual completion of the International search	Dete of mailing of the international search report		
1	16 March 2007	16/08/2007		
Name and	mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer SERRA I VERDA	GUER, J	

#### International application No. PCT/US2007/060581

# INTERNATIONAL SEARCH REPORT

Box ii Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of Invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. Y No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  See additional sheet(s)
Remark on Protest  The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1: claims: 1, 2, 3, 15-20, 21, 22

A stent comprising a drug

2. claims: 1, 4-6, 21, 23

A patch comprising a drug

3. claims: 1, 7, 8, 21, 24

A microsphere comprising a drug

4. claims: 1, 9, 10, 21, 25

A solidifying spray solution comprising a drug

5. claims: 1, 11, 21, 26

An injectable gel comprising a drug

6. claims: 1, 12, 13, 21, 27

An injectable paste comprising a drug

7. claims: 1, 14, 21, 28

An implantable plug comprising a drug

#### INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2007/060581

Patent document clted in search report	Publication date	Patent family member(s)	Publication date
WO 0167991 A	20-09-2001	AU 4356701 A US 6379382 B1 US 2002062147 A1	24-09-2001 30-04-2002 23-05-2002
EP 1518517 A	30-03-2005	NONE	<del></del>
EP 1600125 A	30-11-2005	DE 69926644 D1 DE 69926644 T2 EP 1117351 A2 ES 2247826 T3 JP 2003526392 T WO 0018331 A2	15-09-2005 18-05-2006 25-07-2001 01-03-2006 09-09-2003 06-04-2000
WO 9940874 A	19-08-1999	AT 314023 T AU 754566 B2 AU 2239499 A CA 2322050 A1 CN 1292668 A DE 69929175 T2 EP 1056414 A1 JP 3749437 B2 JP 2002502665 T RU 2217098 C2 US 6033436 A US 6224626 B1	15-01-2006 21-11-2002 30-08-1999 19-08-1999 25-04-2001 22-06-2006 06-12-2000 01-03-2006 29-01-2002 27-11-2003 07-03-2000 01-05-2001
EP 1600122 A	30-11-2005	NONE	<del>-</del>

# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/US2007/060581 16.01.2007 01.02.2006 International Patent Classification (IPC) or both national classification and IPC INV. A61F2/06 Applicant BOSTON SCIENTIFIC SCIMED, INC. This opinion contains indications relating to the following items: 1. ☑ Box No. I Basis of the opinion Box No. II **Priority** ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited Box No. VII Certain defects in the international application ☐ Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office D-80298 Munich

Tel. +49 89 2399 - 0 Tx: 523656 epmu d

Fax: +49 89 2399 - 4465

Date of completion of this opinion

see form PCT/ISA/210 Authorized Officer

SERRA I VERDAGUER, J Telephone No. +49 89 2399-8198



# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2007/060581

	Box	N	p. I Basis of the opinion			
1.	With	ı re	gard to the language, this opinion has been established on the basis of:			
	$\boxtimes$	the	e international application in the language in which it was filed			
		a t pu	ranslation of the international application into , which is the language of a translation furnished for the rposes of international search (Rules 12.3(a) and 23.1 (b)).			
2.	With nec	n re ess	gard to any <b>nucleotide and/or amino acid sequence</b> disclosed in the international application and ary to the claimed invention, this opinion has been established on the basis of:			
	a. ty	pe	of material:			
	[		a sequence listing			
	[		table(s) related to the sequence listing			
	b. format of material:					
	[	]	on paper			
	[		in electronic form			
	c. time of filing/furnishing:					
	ſ	J	contained in the international application as filed.			
	[	]	filed together with the international application in electronic form.			
	Į.		furnished subsequently to this Authority for the purposes of search.			
3.		ha co	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto is been filed or furnished, the required statements that the information in the subsequent or additional pies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.			
4.	Add	litio	nal comments:			

					····				
	Box No	o. IV	Lack of unity of inve	ention					
1. ☑ In response to the invitation (Form PCT/ISA/206) to pay additional fees, the applicant has, within the applicable time limit:						to pay additional fees, the applicant has, within the			
		□ paid additional fees							
paid additional fees under protest and, where applicable, the protest fee									
	applicable protest fee was not paid								
		$\boxtimes$	not paid additional fees	3					
2.	This Authority found that the requirement of unity of invention is not complied with and chose not to invite the applicant to pay additional fees.								
3.	This Au	uthor	rity considers that the re	quiren	nent of unity	of invention in accordance with Rule 13.1, 13.2 and 13.3 is			
	□ com	plie	d with						
	□ not complied with for the following reasons:								
	see separate sheet								
4.	Consequently, this report has been established in respect of the following parts of the international application:								
	□ all parts.								
	Box No		Reasoned statemer applicability; citations	nt und and e	er Rule 43 <i>b</i> explanations	is.1(a)(i) with regard to novelty, inventive step or supporting such statement			
1. Statement									
	Novelt	y (N)		Yes: No:	Claims Claims	1, 2, 3, 15-20, 21, 22			
	Inventi	ve s	tep (IS)	Yes: No:	Claims Claims	1, 2, 3, 15-20, 21, 22			
	Industi	rial a	pplicability (IA)	Yes: No:	Claims Claims	1, 2, 3, 15-20, 21, 22			

2. Citations and explanations

see separate sheet

#### Re Item IV

#### Lack of unity of invention

This Authority considers that there are 7 inventions covered by the claims indicated as follows:

I: Claims 1, 2, 3, 15-20, 21, 22 directed to a stent comprising a drug

II: Claims 1, 4-6, 21, 23 directed to a patch comprising a drug

II: Claims 1, 7, 8, 21, 24 directed to a microsphere comprising a drug

IV: Claims 1, 9, 10, 21, 25 directed to a solidifying spray solution comprising a drug

V: Claims 1, 11, 21, 26 directed to an injectable gel comprising a drug

VI: Claims 1, 12, 13, 21, 27 directed to an injectable paste comprising a drug

VII: Claims 1, 14, 21, 28 directed to an implantable plug comprising a drug

The reasons for which the inventions are not so linked as to form a single general inventive concept, as required by Rule 13.1 PCT, are as follows:

The technical features of the independent claims 1 and 21 are a carrier and an agent formulated to control inflammation provided on the carrier. Claims 1 and 21 are not novel since the features therein disclosed are already known from the prior art (e.g. WO-A-01/67991). Moreover, the concept of providing a drug on a carrier to control inflammation in order to improve the healing process is also already known from the prior art (e.g. WO-A-01/67991). Therefore, lack of unity a posteriori arises since the above groups of claims are neither linked by novel and inventive features nor by a common inventive concept. In conclusion, the groups of claims define 7 different inventions.

The application, hence does not meet the requirements of unity of invention as defined in Rules 13.1 and 13.2 PCT.

#### Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1: WO 01/67991 A (YANG JUN [US]) 20 September 2001 (2001-09-20)

D2: EP-A-1 518 517 (SUN BIOMEDICAL LTD [BM]) 30 March 2005 (2005-03-30)

D3: EP-A-1 600 125 (BARD INC C R [US]) 30 November 2005 (2005-11-30)

D4: WO 99/40874 A (STEINKE THOMAS A [US]) 19 August 1999 (1999-08-19)

D5: EP-A-1 600 122 (MEDTRONIC VASCULAR INC [US]) 30 November 2005 (2005-11-30)

2. The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 1 is not new in the sense of Article 33(2) PCT.

The document D1 discloses (claims 1 and 15): a medical device (100), comprising an agent (104, 106) formulated to control inflammation of heart tissue to prevent the deterioration of myocardial scaffold after a myocardial infarct; and a carrier (102) to which the agent is releasably coupled, the carrier being configured to be disposed in operative proximity to the heart tissue to be treated by the agent.

- 3. The same reasoning applies, mutatis mutandis, to the subject-matter of the corresponding independent claim 21, which therefore is also considered not new.
- 4. Dependent claims 2, 3, 15-20 and 22 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty or inventive step, see documents D1 to D5 and the corresponding passages cited in the search report.